Royalty Report: Drugs, Diagnostic, Drug Discovery – Collection: 369310

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Diagnostic
  • Drug Discovery
  • Disease
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 369310

License Grant
The University grants an exclusive worldwide license to make, have made, use, sell, have sold, offer for sale, import, and otherwise obtain or provide Licensed Products and a non-exclusive worldwide license to use Technical Information.
License Property
The patents and technical information relate to
Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof;
Device and method for treating restenosis;
Inhibition of Phosphatidylinositol 3-kinase with wortmannin analogs;
Device and Method for Treating Restenosis; and,
Wortmannin Analogs and Methods of Using Same.
Field of Use
Licensee is a clinical-stage biopharmaceutical company focused primarily on the development and commercialization of therapeutic products for the treatment of cancer.

IPSCIO Record ID: 369309

License Grant
Universities grant an exclusive, worldwide license to make, have made, use, sell, have sold, offer for sale, import, and otherwise obtain or provide Licensed Products and to use Technology in the Field of Use.
License Property
The patents include
3,4-Dideoxyn Phosphatidylinositol Ether Lipid Analog Inhibitors of Myo-Inositol Cycle;
Deoxy Phosphatidyl Inositol Analogs with Anti tumor Activity;
3-Substituted 3-Deoxy-Phosphatidyl Myo-Inositol Inhibitors of PTEN; and,
Inositol Ether Lipid Analogs and Methods of Using Same.
Field of Use
The Field of Use means any and all fields of use, including the fields of drug design, drug discovery, pharmaceuticals, therapeutics, and diagnostics.

Licensee is a clinical-stage biopharmaceutical company focused primarily on the development and commercialization of therapeutic products for the treatment of cancer.

IPSCIO Record ID: 6906

License Grant
This First Amendment, the University Licensor and Licensee wish to amend the Agreement to add certain Licensed Patents to the Agreement and to amend Fees, Royalties, Payments And Milestones.
License Property
U.S. Patent No. 5,378,725 issued 1/3/1995
assigned to the Arizona Board of Regents and Eli Lilly and Company, now abandoned;
Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof. Abstract – Wortmannin and certain of its analogs are inhibitors of phosphatidylinositol 3-kinase. The compounds are particularly useful for inhibiting phosphatidylinositol 3-kinase in mammals and for treating phosphatidylinositol 3-kinase-dependent conditions, especially neoplasms, in mammals.

    U.S. Patent Application No. 10/245,780 filed
9/16/2002, now U.S. Patent No. 6,703,414 issued 3/09/2004 assigned to
Arizona Board of Regents, and The Burnham Institute;    
    U.S. Patent Application No. 10/245,779 filed
9/16/2002, now U.S. Patent No. 7,081,475 issued 7/25/2006 assigned to Arizona Board of Regents and University of Pittsburgh;    
    U.S. Patent Application No. 11/279,000 filed
4/07/2006, now U.S. Patent No. 7,335,679 issued 2/26/2008 assigned to Arizona Board of Regents and University of Pittsburgh;    
    U.S. Patent Application No. 11/178,553 filed
7/11/2005, now U.S. Patent No. 7,446,124 issued 11/04/2008 assigned to Arizona Board of Regents, Prolx Pharmaceuticals, Inc. and University of Pittsburgh;    
    U.S. Patent Application No. 11/618,036 filed 12/30/2005;    
    U.S. Patent Application No. 11/858,508        
    U.S. Patent Application No. 12/235,730 filed 9/23/20008    
    U.S. Patent Application No. 12/752,935 filed 4/1/2010

Field of Use
The Licensee is a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.